Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Biogen Inc (BIIB) – Biogen Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Biogen (BIIB) trades at $201.96, up 2.42% today, with a bullish technical signal from moving averages and a consensus analyst price target of $230.64. Recent earnings beats in Q3 2025, Q4 2025, and Q1 2026 underscore solid profitability, with a net income margin of 13.81% and robust gross margins of 75.49%. The company is expanding its immunology pipeline through the $1 billion acquisition of RayThera, though it faces ongoing legal investigations.
The outlook for BIIB is positive, supported by strong fundamentals and strategic acquisitions, but risks include legal scrutiny and pipeline execution. Upside potential exists if the company meets earnings expectations and integrates acquisitions successfully, while downside risks stem from regulatory and competitive pressures.
Read full analysis

Key Stats

  • Market Cap
    $29.47B
  • Sector
    Health
  • 3M Drawdown
    -9.8%
  • Enterprise Value
    $31.75B
  • Dividend Yield
    -
  • Typical Hold Time
    110 days
$201.46
52W Low: $122.68
21 Jul 2025
52W High: $204.53
13 May 2026

Biogen Inc (BIIB) is currently valued at a market capitalization of $29.47B, with an enterprise value of $31.75B. Over the past 52 weeks, Biogen Inc has traded between a low of $122.68 and a high of $204.53, highlighting its annual price range. Over the past three months, Biogen Inc has recorded a drawdown of -9.8%, reflecting recent price volatility. On average, investors hold Biogen Inc for approximately 110 days, indicating typical investor behavior on the platform.

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.


People also bought


Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Key Stats

  • Market Cap
    $29.47B
  • Sector
    Health
  • 3M Drawdown
    -9.8%
  • Enterprise Value
    $31.75B
  • Dividend Yield
    -
  • Typical Hold Time
    110 days
$201.46
52W Low: $122.68
21 Jul 2025
52W High: $204.53
13 May 2026

Biogen Inc (BIIB) is currently valued at a market capitalization of $29.47B, with an enterprise value of $31.75B. Over the past 52 weeks, Biogen Inc has traded between a low of $122.68 and a high of $204.53, highlighting its annual price range. Over the past three months, Biogen Inc has recorded a drawdown of -9.8%, reflecting recent price volatility. On average, investors hold Biogen Inc for approximately 110 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!